30 results about "Hepatitis D" patented technology

The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E). Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

A method for the treatment for hepatitis delta infection in a host, that includes administering an effective amount of a nucleoside or a nucleoside analog that suppresses the expression of the hepatitis B surface or preS1 antigen in the host 100-fold or more relative to pretreatment values in vivo; or to not more than 1 microgram per milliliter in vivo. In a preferred embodiment, the nucleoside is L-FMAU, or a pharmaceutically acceptable salt or prodrug thereof.

An inactivated Polio Vaccine derived from Sabin strain for safe and effective immunization against Poliomyelitis is provided. A process of preparation for such vaccine and formulations thereof are also provided. Administration of the vaccine of the present invention along with other antigens provides immunization not only against polio infection but also against other pathogens causing Hepatitis C. Hepatitis D. Hepatitis E. Meningitis A. Meningitis B. Meningitis C. Meningitis W. Meningitis Y. Pnemococcal (23 valent or more). Smallpox, Typhoid, Bacille Calmette Guerin, Tuberculosis. Human Immunodeficiency Virus. Anthrax or the like, to which children or adults not immunized earlier are susceptible, particularly to which children are susceptible.

The invention discloses a canine distemper virus CDV-3 strain infectious cDNA cloning and constructing method and application thereof. A canine distemper virus CDV-3 strain is used as a template, theoverall length of the CDV-3 is divided into 5 fragments, and RT-PCR amplification is performed. Through enzyme-cutting splicing, the 5 fragments are sequentially inserted into a eukaryotic vector, besides, a hammerhead ribozyme sequence and a hepatitis D ribozyme sequence are respectively added to an F1 head end and an F5 tail end, and canine distemper virus CDV-3 strain infectious cDNA clone is obtained; then three auxiliary plasmids expressing CDV-3N, P and L proteins are constructed; the canine distemper virus CDV-3 infectious cDNA clone and the three auxiliary plasmids are used for performing cotransfection on 293T cells so that saved recombinant CDV-3 viruses (rCDV-3) are obtained. Through research, the highest titer of the obtained rCDV-3 virus can reach 107.667TCID50/mL, which is 10times higher than that of wtCDV-3. After Vero cells are infected with the rCDV-3, within 36h after infection, the highest virus titer can be achieved; but after the Vero cells are infected with the wtCDV-3, within 72h after infection, the virus content can reach the highest value. A base is established for developing a canine distemper virus novel vaccine and studying the infective mechanism through the canine distemper virus CDV-3 strain infectious cDNA cloning and constructing method disclosed by the invention.

Disclosed herein are chimeric genes, compositions of chimeric genes, and compositions of polypeptides that are useful for the generation, enhancement, or improvement of an immune response to a target antigen. Some embodiments of the compositions include chimeric genes encoding hepatitis D antigen (HDAg) protein in combination with one or more self-cleavage 2A polypeptides and a preS 1 polypeptide. In certain embodiments the self-cleavage polypeptide is P2A.

The method and composition for treating a host infected with hepatitis D, comprising administering the 2'-deoxy-β-L-erythro-pentofuranose nucleoside or a pharmaceutically acceptable salt or prodrug thereof in an effective amount for treating hepatitis D.

It is disclosed a method for treating hepatitis B virus infection or hepatitis B virus/hepatits delta virus co-infection, the method comprising administering to a subject in need of such treatment a first pharmaceutically acceptable agent that comprises at least one phosphorothioated nucleic acid polymer and a second pharmaceutically acceptable agent that comprises at least one nucleoside/nucleotide analog HBV polymerase inhibitor.

A disclosed medicine capable of treating hepatopathy comprises split-charged snorting composition, hot compress composition and oral composition; the snorting composition is melon pedicle powder; the hot compress composition is prepared by mixing and crushing 2-4 parts by weight of radix bupleuri, 2-4 parts by weight of catnip, 10-14 parts by weight of toona sinensis root bark, 0.02-0.1 part of calculus bovis and 0.5-2 parts of excrementum passeris; and the oral composition is a leaching liquid obtained by adding water into raw watermelon seeds and decocting. The provided medicine capable of treating hepatopathy is capable of effectively treating various hepatopathy, such as hepatitis A, hepatitis B, hepatitis C, hepatitis D, alcoholic fatty liver, liver cirrhosis early stage, icteric hepatitis and persistent hepatitis.

The invention relates to a method for rapidly constructing a reverse genetic strain of a duck hepatitis A virus type 3. A whole genome of the duck hepatitis A virus type 3 is divided into three segments with similar size for PCR amplification, a cytomegalovirus immediate early promoter is added at a 5' end of the first segment, synonymous mutation is introduced into a 2A gene of the second segmentto serve as a genetic marker locus, a hepatitis delta virus ribozyme sequence and an SV40 early mRNA polyadenylation signal sequence are added to a 3' end of the third segment of the genome of the virus, the construction of an infective subgenome replicon of the duck hepatitis A virus type 3 is completed, the infective subgenome replicon is mixed with a transfection reagent to transfect an original duck embryo fibroblast, the replicon is spontaneously recombined, and finally, a duck hepatitis A virus type 3 with a genetic marker is obtained. By means of the method, the mutant strain of the duck hepatitis A virus type 3 can be quickly obtained, and a favorable tool is provided for studying the pathogenic mechanism of the duck hepatitis A virus type 3 and developing a novel vaccine.

The present disclosure relates to compositions and methods for treating viral infections and in particular for treating hepatitis B and hepatitis D viral infections. A method of treating a hepatitis B virus infection in a subject the method comprising administering to the subject an inhibitor wherein the inhibitor inhibits or suppresses a regulator of liver lipid metabolism in the subject.

The present invention relates to a polypeptide and a nucleic acid encoding the polypeptide for use in a method of detecting the presence of hepatitis D vims (HDV) and/or of diagnosing an HDV infection and/or of monitoring the treatment of an HDV infection. The present invention further relates to an in vitro method, an immunographic test device as well as a kit. In particular, the present invention relates to a point of care diagnostic for HDV infections.

The invention provides therapeutic combinations and therapeutic methods that are useful for treating Hepatitis B and Hepatitis D.